EIP Pharma flies into a high-risk PhIIb Alzheimer’s study fueled with $20.5M from billionaire Len Blavatnik’s Access Industries
Undeterred by the string of failures plaguing Alzheimer’s drug development, a young startup based in Cambridge, MA has tapped an unconventional source for $20.5 million to advance a repurposed drug in the clinic.
The new funds — coming from billionaire Len Blavatnik’s Access Industries — will power EIP Pharma’s Phase IIb study of neflamapimod, a p38 kinase inhibitor in-licensed from Vertex Pharma. Named REVERSE-SD, the high-risk trial will measure improvement in episodic memory as a primary endpoint and have several secondary endpoints including Clinical Dementia Rating Scale Sum-of-Boxes, Wechsler Memory Scale, and spinal fluid biomarkers of disease progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.